Physician profile
Patrick Alan Spencer
NPI 1013164110
$5,446.31
in general payments reported to CMS, 2019-2025
14 companies · $1,301 in 2025
The $1,301 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $347 · 2022: $906 · 2023: $1,510 · 2024: $1,381 · 2025: $1,301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,492 · Education: $361 · Consulting Fee: $340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,491.67 |
| Education | $360.99 |
| Consulting Fee | $340.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,091.48 | 2021-2025 | Darzalex, Tecvayli, Talvey |
| Genzyme Corporation | $778.10 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $455.27 | 2023-2024 | Carvykti, Talvey |
| Takeda Pharmaceuticals U.S.A., INC. | $452.51 | 2023-2025 | Ninlaro |
| Celgene Corporation | $424.37 | 2021-2024 | Pomalyst |
| Karyopharm Therapeutics INC. | $403.97 | 2022-2025 | Xpovio |
| Amgen INC. | $200.22 | 2021-2025 | Tepezza, Xgeva |
| Legend Biotech USA INC. | $189.05 | 2024-2025 | Carvykti |
| Kite Pharma, INC. | $139.19 | 2025 | |
| Glaxosmithkline, LLC. | $124.44 | 2022 | |
| Pfizer INC. | $99.94 | 2023-2025 | |
| Adaptive Biotechnologies Corporation | $49.48 | 2025 | Clonoseq |
| Bayer Healthcare Pharmaceuticals INC. | $19.42 | 2022 | |
| Merck Sharp & Dohme LLC | $18.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Spencer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.